EBQ:IST-3 - Revision history

Danbot: Completed empty sections: Major Points, Interventions, Outcomes, Criticisms

2026-03-21T22:46:00Z

Completed empty sections: Major Points, Interventions, Outcomes, Criticisms

← Revisión anterior		Revisión del 22:46 21 mar 2026
Línea 23:		Línea 23:

	==Major Points==		==Major Points==
			*IST-3 was the largest randomized trial of IV alteplase for acute ischemic stroke, including patients >80 years old
			*The primary outcome (alive and independent at 6 months, Oxford Handicap Score 0-2) did not reach statistical significance (OR 1.13, 95% CI 0.95-1.35, p=0.181)
			*Ordinal analysis showed a significant shift toward better functional outcomes with alteplase (OR 1.27, 95% CI 1.10-1.47)
			*Early hazard: significantly more symptomatic intracranial hemorrhage within 7 days in the alteplase group (7% vs 1%)
			*The trial extended the evidence base for thrombolysis in patients aged >80 years, where prior trials had limited enrollment

	==Study Design==		==Study Design==
Línea 40:		Línea 44:


	==Interventions==		==Interventions==
			*IV alteplase (0.9 mg/kg, max 90 mg; 10% bolus, remainder over 60 minutes) within 6 hours of stroke onset
			*Control group: standard care without alteplase (open-label)
			*Aspirin was withheld for 24 hours after alteplase administration
			*All patients received standard stroke unit care

	==Outcome==		==Outcomes==
			===Primary Outcome===
			*Alive and independent at 6 months (OHS 0-2): alteplase 554/1515 (37%) vs control 534/1520 (35%)
			*Adjusted OR 1.13 (95% CI 0.95-1.35, p=0.181) - not statistically significant
			===Secondary Outcomes===
			*Ordinal shift analysis favored alteplase: common OR 1.27 (95% CI 1.10-1.47, p=0.001)
			*Symptomatic intracranial hemorrhage within 7 days: 7% alteplase vs 1% control
			*Mortality at 6 months: 27% alteplase vs 27% control (no difference)
			*Deaths within 7 days: 11% alteplase vs 7% control (higher early mortality with alteplase)

	===Primary Outcomes===		===Primary Outcomes===
Línea 59:		Línea 72:

	==Criticisms==		==Criticisms==
			*Open-label design introduces potential for bias in post-stroke care decisions
			*Extended treatment window up to 6 hours included patients where benefit of thrombolysis is less established
			*Primary endpoint did not reach statistical significance; the positive ordinal analysis was a secondary outcome
			*Higher rate of symptomatic intracranial hemorrhage raises safety concerns, particularly in elderly patients
			*The trial was underpowered for its original primary outcome due to slower than expected recruitment

	==Funding==		==Funding==

Danbot: Mark as Complete - article has all required sections

2026-03-21T22:12:04Z

Mark as Complete - article has all required sections

← Revisión anterior		Revisión del 22:12 21 mar 2026
Línea 13:		Línea 13:
	\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext		\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext
	\| pdfurl=		\| pdfurl=
			\| status = Complete
	}}		}}

Cchoff: EBQ

2014-11-08T01:51:32Z

EBQ

← Revisión anterior		Revisión del 01:51 8 nov 2014
Línea 28:		Línea 28:
	*open treatment		*open treatment

	==Inclusion Criteria==		==Inclusion Criteria==
			*Signs and symptoms of acute stroke
			*Known time of stroke onset
			*Treatment could be started within 6 hours of onset
			*CT or MRI excluded ICH and brain lesion
			*Patient and clinician felt the treatment was "promising but unproven"
			*If patient had indication for IV thrombolysis- treated with local guidelines

	==Exclusion Criteria==		==Exclusion Criteria==

Cchoff: EBQ

2014-11-08T01:48:30Z

EBQ

← Revisión anterior		Revisión del 01:48 8 nov 2014
Línea 21:		Línea 21:
	Thrombolysis within 6 hours improved functional outcome even though there were early hazards. This applies to the population of patients recruited for IST-3, benefits appear to be seen in the elderly as well.		Thrombolysis within 6 hours improved functional outcome even though there were early hazards. This applies to the population of patients recruited for IST-3, benefits appear to be seen in the elderly as well.

	==Major Points==		==Major Points==


			==Study Design==
			*International, randomized controlled trial
			*open treatment

	==Inclusion Criteria==		==Inclusion Criteria==

Cchoff: EBQ

2014-11-08T01:38:46Z

EBQ

← Revisión anterior		Revisión del 01:38 8 nov 2014
Línea 19:		Línea 19:

	==Conclusion==		==Conclusion==
			Thrombolysis within 6 hours improved functional outcome even though there were early hazards. This applies to the population of patients recruited for IST-3, benefits appear to be seen in the elderly as well.

	==Major Points==		==Major Points==

Cchoff: EBQ

2014-11-04T06:08:24Z

EBQ

← Revisión anterior		Revisión del 06:08 4 nov 2014
Línea 16:		Línea 16:

	==Clinical Question==		==Clinical Question==
			Can use of fibrinolytics for acute ischemic stroke be extended to a wider range of patients up to 6 hours?

	==Conclusion==		==Conclusion==

Rossdonaldson1: Rossdonaldson1 moved page IST-3 to EBQ:IST-3

2013-12-02T00:01:14Z

Rossdonaldson1 moved page IST-3 to EBQ:IST-3

← Revisión anterior	Revisión del 00:01 2 dic 2013
(Sin diferencias)

Ostermayer at 17:14, 13 November 2013

2013-11-13T17:14:31Z

← Revisión anterior		Revisión del 17:14 13 nov 2013
Línea 13:		Línea 13:
	\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext		\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext
	\| pdfurl=		\| pdfurl=
	~~\| status = Under Review~~
	}}		}}

Ostermayer at 17:10, 13 November 2013

2013-11-13T17:10:32Z

← Revisión anterior		Revisión del 17:10 13 nov 2013
Línea 13:		Línea 13:
	\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext		\| fulltexturl= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60768-5/fulltext
	\| pdfurl=		\| pdfurl=
			\| status = Under Review
	}}		}}

Ostermayer: /* Funding */

2013-11-04T04:56:14Z

Funding

← Revisión anterior		Revisión del 04:56 4 nov 2013
Línea 53:		Línea 53:

	==Funding==		==Funding==
	UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden, Swedish Heart Lung Fund, The Foundation of Marianne and Marcus Wallenberg, Polish Ministry of Science and Education, the Australian Heart Foundation, Australian National Health and Medical Research Council (NHMRC), Swiss National Research Foundation, Swiss Heart Foundation, Assessorato alla Sanita, Regione dell'Umbria, Italy, and Danube University.		UK Medical Research Council, Health Foundation UK, Stroke Association UK, Research Council of Norway, Arbetsmarknadens Partners Forsakringsbolag (AFA) Insurances Sweden, Swedish Heart Lung Fund, The Foundation of Marianne and Marcus Wallenberg, Polish Ministry of Science and Education, the Australian Heart Foundation, Australian National Health and Medical Research Council (NHMRC), Swiss National Research Foundation, Swiss Heart Foundation, Assessorato alla Sanita, Regione dell'Umbria, Italy, and Danube University.

	==Sources==		==Sources==